Pacor M L, Biasi D, Cortina P, Maleknia T, Lunardi C
Istituto di Clinica Medica, Università degli Studi di Venezia.
Clin Ter. 1994 Aug;145(8):131-4.
Inhaled beta 2-agonists play a central role in the treatment of acute bronchial asthma. A new long-acting beta 2-receptor agonist has recently become available: salmeterol. It improves FEV 1, has an antiinflammatory effect on bronchial airways, provides a strong protection against histamine-and allergen-triggered bronchoconstriction, thus leading to better control of asthmatic symptoms during day and night. The aim of this study was to evaluate the efficacy of salmeterol in 22 patients with allergic bronchial asthma. Our results show that inhaled salmeterol (50 micrograms twice daily) can successfully control diurnal and nocturnal asthmatic attacks and can induce an important increase of PEFR. During the study no further treatment with bronchodilator drugs was necessary.
吸入型β2 激动剂在急性支气管哮喘的治疗中起着核心作用。一种新型长效β2 受体激动剂最近已上市：沙美特罗。它可改善第一秒用力呼气容积（FEV1），对支气管气道有抗炎作用，能有效预防组胺和过敏原引发的支气管收缩，从而更好地控制昼夜哮喘症状。本研究的目的是评估沙美特罗对 22 例过敏性支气管哮喘患者的疗效。我们的结果表明，吸入沙美特罗（每日两次，每次 50 微克）可成功控制昼夜哮喘发作，并能使呼气峰值流速（PEFR）显著增加。在研究期间，无需进一步使用支气管扩张剂药物治疗。
